Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 10
Submit an article Journal homepage
140
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluation

Imatinib mesylate in the treatment of hematologic malignancies

Pier Paolo Piccaluga Institute of Haematology and Medical Oncology ‘L and A Seràgnoli’, S. Orsola-Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 – 40138 Bologna, Italy +39 051 6364043; +39 051 6364037; [email protected]
, MD PhD,
Michela Rondoni Institute of Haematology and Medical Oncology ‘L and A Seràgnoli’, S. Orsola-Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 – 40138 Bologna, Italy +39 051 6364043; +39 051 6364037; [email protected]
, MD,
Stefania Paolini Institute of Haematology and Medical Oncology ‘L and A Seràgnoli’, S. Orsola-Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 – 40138 Bologna, Italy +39 051 6364043; +39 051 6364037; [email protected]
, MD,
Gianantonio Rosti Institute of Haematology and Medical Oncology ‘L and A Seràgnoli’, S. Orsola-Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 – 40138 Bologna, Italy +39 051 6364043; +39 051 6364037; [email protected]
, MD,
Giovanni Martinelli Institute of Haematology and Medical Oncology ‘L and A Seràgnoli’, S. Orsola-Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 – 40138 Bologna, Italy +39 051 6364043; +39 051 6364037; [email protected]
, MD &
Michele Baccarani Institute of Haematology and Medical Oncology ‘L and A Seràgnoli’, S. Orsola-Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 – 40138 Bologna, Italy +39 051 6364043; +39 051 6364037; [email protected]
, MD
Pages 1597-1611 | Published online: 05 Oct 2007

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Mauricio P. Pinto, Gareth I. Owen, Ignacio Retamal & Marcelo Garrido. (2017) Angiogenesis inhibitors in early development for gastric cancer. Expert Opinion on Investigational Drugs 26:9, pages 1007-1017.
Read now
Pier Paolo Piccaluga, Stefania Paolini, Clara Bertuzzi, Antonio De Leo & Gianantonio Rosti. (2012) First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. Journal of Blood Medicine 3, pages 151-156.
Read now
Subbareddy Maddika, Soumya Panigrahi, Emilia Wiechec, Sebastian Wesselborg, Ute Fischer, Klaus Schulze-Osthoff & Marek Los. (2009) Unscheduled Akt-Triggered Activation of Cyclin-Dependent Kinase 2 as a Key Effector Mechanism of Apoptin's Anticancer Toxicity. Molecular and Cellular Biology 29:5, pages 1235-1248.
Read now

Articles from other publishers (16)

Adriatik Berisha, Angelo Placci & Pier Paolo Piccaluga. (2023) Cardiotoxicity of Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients. Hemato 4:1, pages 68-75.
Crossref
Brittany Salter, Ian Burns, Katherine Fuller, Ali Eshaghpour, Anath C. Lionel & Mark Crowther. (2022) Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review. European Journal of Haematology 109:2, pages 166-181.
Crossref
EmineElif Altuntas, Kasim Durmus, Adem Bora, NergizHacer Turgut, Hatice Terzi & Ahmet Kutluhan. (2020) Examination of ototoxicity induced by imatinib, being a tyrosine kinase inhibitor: An experimental study. Indian Journal of Otology 26:3, pages 141.
Crossref
Nora S Sánchez, Gordon B Mills & Kenna R Mills Shaw. (2017) Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics 18:16, pages 1525-1539.
Crossref
Alison C. Macleod, Lillian R. Klug & Michael C. Heinrich. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets 683 692 .
Priscila Da Silva Figueiredo Celestino Gomes, Isaure Chauvot De Beauchêne, Nicolas Panel, Sophie Lopez, Paulo De Sepulveda, Pedro Geraldo Pascutti, Eric Solary & Luba Tchertanov. (2016) Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT. PLOS ONE 11:7, pages e0160165.
Crossref
Alison C. Macleod, Lillian R. Klug & Michael C. Heinrich. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets 1 9 .
Mauricio P Pinto, Wendy W Dye, Britta M Jacobsen & Kathryn B Horwitz. (2014) Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling. BMC Cancer 14:1.
Crossref
Juliet Fraser Gibson, Francine Foss, Dennis Cooper, Stuart Seropian, Diana Irizarry, Lisa Barbarotta & Frederick Lansigan. (2014) Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. British Journal of Haematology 167:1, pages 141-144.
Crossref
Sophie Georgin-LavialleLudovic LhermittePatrice DubreuilMarie-Olivia ChandesrisOlivier Hermine & Gandhi Damaj. (2013) Mast cell leukemia. Blood 121:8, pages 1285-1295.
Crossref
Inken Wierstra. 2013. 191 419 .
Annelies Fieuw, Candy Kumps, Alexander Schramm, Filip Pattyn, Björn Menten, Francesca Antonacci, Peter Sudmant, Johannes H. Schulte, N Van Roy, Sarah Vergult, Patrick G. Buckley, A De Paepe, Rosa Noguera, Rogier Versteeg, Raymond Stallings, Angelika Eggert, Jo Vandesompele, K De Preter & Frank Speleman. (2011) Identification of a novel recurrent 1q42.2‐1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas . International Journal of Cancer 130:11, pages 2599-2606.
Crossref
Stefania Paolini, Anna Gazzola, Elena Sabattini, Francesco Bacci, Stefano Pileri & Pier Paolo Piccaluga. (2011) Pathobiology of acute lymphoblastic leukemia. Seminars in Diagnostic Pathology 28:2, pages 124-134.
Crossref
David S. Bosler. 2011. Hematopathology. Hematopathology 215 253 .
Arturo Vega-Ruiz, Jorge E. Cortes, Matjaz Sever, Taghi Manshouri, Alfonso Quintás-Cardama, Raja Luthra, Hagop M. Kantarjian & Srdan Verstovsek. (2009) Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leukemia Research 33:11, pages 1481-1484.
Crossref
Valerie I. Brown, Alix E. Seif, Gregor S. D. Reid, David T. Teachey & Stephan A. Grupp. (2008) Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunologic Research 42:1-3, pages 84-105.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.